Bill: HB 3388, 86(R) - 2019

Committee

House Public Health

2nd Chamber Committee

Senate Health & Human Services

Vote Recommendation

Vote Recommendation Economic Freedom Property Rights Personal Responsibility Limited Government Individual Liberty
No Neutral Neutral Neutral Negative Neutral

Author(s)

J.D. Sheffield
Greg Bonnen
Cole Hefner
Four Price
Richard Raymond

Co-Author(s)

Trent Ashby
Armando Martinez
Rick Miller
Tan Parker
Gary VanDeaver
Bill Zedler

Sponsor(s)

Lois Kolkhorst

Bill Caption

Relating to delivery of outpatient prescription drug benefits under certain public benefit programs, including Medicaid and the child health plan program.

Fiscal Notes

According to the Legislative Budget Board, there would be a negative impact of ($8,172,748) through the biennium ending August 31, 2021.

Bill Analysis

HB 3388 would revise the guidelines for the reimbursement of prescription drugs under certain public benefit programs. More specifically, it would require the Health and Human Services Commission to mandate that managed care organizations (MCOs) providing services under Medicaid or the Children's Health Insurance Program (CHIP) reimburse pharmacies a minimum of the lesser of: (1) the reimbursement amount for the drug in the vendor drug program or (2) the amount claimed by the pharmacy or pharmacist. The bill would also require MCOs to reimburse pharmacies that dispense a prescription drug at a discounted price not less than the reimbursement amount for the drug under the vendor drug program.

Vote Recommendation Notes

As the fiscal note makes clear, HB 3388 would significantly increase the cost of prescription drug benefits under the Medicaid and CHIP programs. This is out of alignment with our limited government liberty principle, therefore, we oppose HB 3388.


Source URL (retrieved on 04/23/2024 11:04 PM): http://reports.texasaction.com/bill/86r/hb3388?print_view=true